0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead's BIC LEN HIV Results Highlight Valuation Gap And Future Potential [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Gilead Sciences reported positive Phase 3 results for its BIC/LEN HIV regimen at CROI 2026. The ARTISTRY-1 and ARTISTRY-2 trials showed efficacy and safety in line with current complex and single tablet HIV therapies. BIC/LEN is a once daily single tablet option aimed at people living with HIV, including those currently on multi pill regimens. For investors watching Gilead Sciences, NasdaqGS:GILD, the BIC/LEN data adds a fresh clinical milestone to an already established HIV franchise. The company's shares recently traded at $143.93, with a 26.0% return over the past year and a very large 3 year gain of about 7x. Over 5 years, the stock shows a 180.1% return, which underlines how HIV research has remained central to the story. Short term returns have been softer, with a 3.4% decline over the past week and a 3.6% decline over the past month, while the stock is still up [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead's BIC LEN HIV Results Highlight Valuation Gap And Future Potential [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Gilead Sciences reported positive Phase 3 results for its BIC/LEN HIV regimen at CROI 2026. The ARTISTRY-1 and ARTISTRY-2 trials showed efficacy and safety in line with current complex and single tablet HIV therapies. BIC/LEN is a once daily single tablet option aimed at people living with HIV, including those currently on multi pill regimens. For investors watching Gilead Sciences, NasdaqGS:GILD, the BIC/LEN data adds a fresh clinical milestone to an already established HIV franchise. The company's shares recently traded at $143.93, with a 26.0% return over the past year and a very large 3 year gain of about 7x. Over 5 years, the stock shows a 180.1% return, which underlines how HIV research has remained central to the story. Short term returns have been softer, with a 3.4% decline over the past week and a 3.6% decline over the past month, while the stock is still up [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS